Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody (GB221) for Injection
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: HER-2-positive Advanced Breast Cancer
Interventions: DRUG: GB221|DRUG: Placebo control
Sponsor: Genor Biopharma Co., Ltd.